{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:18:06Z","timestamp":1787987886857,"version":"build-2784847793"},"reference-count":15,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Management of uveitis displays a particular challenge in childhood. This study aims to compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in pediatric noninfectious uveitis that were refractory to conventional immunosuppresives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective single-center study included 33 patients who were treated with anti-tumor necrosis factor (TNF) agents (16 with IFX and 17 with ADA). Patients had diverse etiologies, including juvenile idiopathic arthritis, idiopathic uveitis, and Beh\u00e7et's disease. Demographic characteristics, systemic diagnosis, findings of the ophthalmological examination, control of ocular inflammation, response to treatment, and the rate of clinical remission were studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Fourteen (87.5%) patients receiving IFX and 10 (58.8%) patients receiving ADA achieved response to treatment during the follow-up (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.118). The agents were discontinued with complete clinical remission in 6 (37.5%) patients receiving IFX and in 2 (11.8%) patients receiving ADA (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.118). Baseline visual acuities and parameters of inflammation improved significantly in both groups after anti-TNF therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Both IFX and ADA are safe and effective for pediatric noninfectious uveitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2020.0081","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T09:43:05Z","timestamp":1611913385000},"page":"236-240","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab"],"prefix":"10.1177","volume":"37","author":[{"given":"Gamze","family":"Ucan Gunduz","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Uludag University School of Medicine, Bursa, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Yalcinbayir","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Uludag University School of Medicine, Bursa, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukru","family":"Cekic","sequence":"additional","affiliation":[{"name":"Uludag University School of Medicine, Pediatric Allergy and Clinical Immunology, Bursa, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Uludag University School of Medicine, Bursa, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara S.","family":"Kilic","sequence":"additional","affiliation":[{"name":"Uludag University School of Medicine, Pediatric Immunology and Rheumatology, Bursa, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"259","article-title":"Pediatric uveitis","volume":"6","author":"Tugal-Tutkun I.","year":"2011","unstructured":"Tugal-Tutkun I. Pediatric uveitis. J. Ophthalmic Vis. Res. 6:259\u2013269, 2011.","journal-title":"J. Ophthalmic Vis. Res"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.icu.0000177414.79030.32"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.3229"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4228-6"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-016-0069-5"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-017-0057-z"},{"key":"e_1_3_3_8_2","first-page":"509","article-title":"Standardization of nomenclature for reporting clinical data","volume":"140","author":"Jabs D.","year":"2005","unstructured":"Jabs D., , Nussenblatt R.B., , and Rosenbaum J.T. Standardization of nomenclature for reporting clinical data. Results of the First International Workshop. Am. J. Ophthalmol., 140:509\u2013516, 2005.","journal-title":"Results of the First International Workshop. Am. J. Ophthalmol."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1606256"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4133-z"},{"key":"e_1_3_3_11_2","first-page":"1685","article-title":"An update on the modern management of paediatric uveitis","volume":"103","author":"Choi J.","year":"2019","unstructured":"Choi J., , Hawley D.P., , Ashworth J., , Edelsten C., , and Bossuyt A.S.A.M. An update on the modern management of paediatric uveitis. Br. J. Ophthalmol. 103:1685\u20131689, 2019.","journal-title":"Br. J. Ophthalmol"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20404"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120583"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-018-3928-6"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.09581"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.04.016"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2020.0081","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:44:11Z","timestamp":1777646651000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2020.0081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5,1]]}},"alternative-id":["10.1089\/jop.2020.0081"],"URL":"https:\/\/doi.org\/10.1089\/jop.2020.0081","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}